Skip to content
Open access

Cost-effectiveness of RSVpreF for the prevention of respiratory syncytial virus illness among high-risk adults in Germany.

Jul 2026 · Expert Review of Vaccines · Vol 25 1, pp. 2708199 · 0 citations · 35 references
Medicine

TL;DR

Expanding the recommendation to include IC or CMC+/IC adults aged 18-59 years could substantially reduce the clinical burden of RSV-LRTI in Germany; including IC 18-59-year-olds would also be cost-saving.

Abstract

INTRODUCTION Vaccination against lower respiratory tract illness due to respiratory syncytial virus (RSV-LRTI) is approved in Europe for all adults aged ≥18 years. The German Standing Committee on Vaccination (STIKO), however, only recommends vaccination for high-risk adults aged 60-74 years and all adults aged ≥75 years (standard of care [SOC]). Younger, immunocompromised adults [IC], as well as those with chronic medical conditions [CMC+], remain unprotected. RESEARCH

Design

AND

Methods

A multi-cohort model projected lifetime RSV-related clinical and economic outcomes (in 2025 €) among adults in Germany. Base case analyses considered the cost-effectiveness of adding vaccination of IC adults aged 18-59 years to the SOC from a societal perspective. An expanded base case adding CMC+/IC adults aged 18-59 years to the SOC was also evaluated.

Results

Adding IC adults aged 18-59 years to the recommendation would prevent 6,490 additional cases, avert 199 more deaths, and reduce costs by 21 million € compared to the SOC. Incorporating CMC+/IC adults would prevent 24,545 additional cases and 388 deaths, at an incremental cost of 238 million €.

Conclusions

Expanding the recommendation to include IC or CMC+/IC adults aged 18-59 years could substantially reduce the clinical burden of RSV-LRTI in Germany; including IC 18-59-year-olds would also be cost-saving.

Read PDF

Similar papers

Open access Sep 2026

Clinical and economic benefits of bivalent Respiratory syncytial virus prefusion F (RSVpreF) vaccine for prevention of RSV in adults: a cost-effectiveness analysis for Singapore.

RSVpreF vaccination would substantially reduce the clinical and economic burden of RSV among adults in Singapore and be cost-effective under a threshold of 1 ×gross domestic product per capita per QALY gained.

K. Thakkar, A. Shajarizadeh, Nishu Gaind et al. · 0 citations
Open access Aug 2026

Cost-Effectiveness Analysis of the mRNA-1345 RSV Vaccine for Older Adults in Italy

Vaccination with mRNA-1345 is a cost-effective strategy for the prevention of RSV in high-risk adults aged 60-74 years and all adults aged [≥]75 years in Italy and has the potential to provide substantial public health benefits.

M. Dronova, C. Moyon, L. Pyrek et al. · 0 citations
Open access Sep 2026

Clinical and economic impact of bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccination in older adults: a cost-effectiveness analysis for Chile.

BACKGROUND Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract disease in older adults in Chile. Chile's National Immunization Technical Advisory Group (NITAG) recommended RSV vaccination for adults aged ≥60 years with risk factors for severe illness. This study estimated the cost-effectivenes...

Rafael Bolaños, Tomas Eduardo Abbott, A. Shajarizadeh et al. · 0 citations
Review Open access Oct 2026

Respiratory Syncytial Virus Vaccines: Who, When, and Which Vaccine? A Practical Guide for Clinicians

Respiratory syncytial virus (RSV) is a major cause of severe respiratory illness and hospitalization in older adults with chronic cardiopulmonary or metabolic conditions. After six decades without a preventive option, three RSV vaccines are now available: an adjuvanted prefusion F protein vaccine (Arexvy), a bivalent p...

Raeseok Lee · 0 citations
#protein folding Open access Oct 2026

RSV prefusion F vaccine effectiveness in older adults with immunosuppression: a prespecified analysis of the DAN-RSV trial.

In adults aged 60 years or older, RSVpreF vaccination reduced hospitalisations for RSV-related respiratory tract disease with no statistical evidence of effect modification by immunosuppression status; however, the study was not powered to exclude subgroup differences.

A. Reimer Jensen, M. H. Højbjerg Lassen, N. Johansen et al. · 0 citations
Review Sep 2026

[Vaccination against respiratory infections in older adults: Covid-19, respiratory syncytial virus, influenza and pneumococcus].

This review provides an update on four vaccine-preventable respiratory infections that are particularly common or severe in older adults: coronavirus disease 2019 (COVID-19), respiratory syncytial virus (RSV) infection, seasonal influenza, and pneumococcal disease.

M. Paccalin, P. Loubet · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.